Health Rounds: Death from dementia on the rise among people with type 2 diabetes
AstraZenecaAstraZeneca(US:AZN) Reuters·2026-03-11 11:28

Group 1 - The analysis indicates that while deaths from cardiovascular disease among type 2 diabetes patients in wealthy countries are declining, mortality from dementia is increasing [1][4] - New diabetes medications, such as GLP-1s and SGLT-2 inhibitors, provide heart protection but are not designed to protect cognitive health [2][3] - The study analyzed data from 2.7 million deaths of type 2 diabetes patients between 2000 and 2023, revealing a clear trend towards increased dementia-related mortality [4] Group 2 - A separate study suggests that low testosterone levels in prostate cancer patients under active surveillance may indicate a higher risk of disease progression to more aggressive forms [5][6] - The study found that testosterone levels of 300 nanograms per deciliter or lower were linked to an increased likelihood of progression to Grade 3 prostate cancer [5] - Understanding hormonal influences on prostate cancer could refine monitoring strategies for patients [6] Group 3 - A study predicts that climate change could lead to significant mental health impacts, resulting in hundreds of millions of additional days of anxiety and depression symptoms in the U.S. [8][10] - The analysis estimates that annual warming of 1 to 6 degrees Celsius could result in up to 1.8 billion additional anxiety symptom-days and up to 1.4 billion additional depression symptom-days [9] - The findings highlight the need for increased mental health investment, particularly in economically vulnerable regions [10]

AstraZeneca-Health Rounds: Death from dementia on the rise among people with type 2 diabetes - Reportify